Macular Edema, Diabetic Retinopathy, Macular Degeneration
Conditions
Keywords
bevacizumab, intra-ocular pressure, acetazolamide, anterior chamber paracentesis, brimonidine, macular edema secondary to diabetic retinopathy or macular degeneration
Brief summary
Purpose: To evaluate the effects of anterior chamber paracentesis, brimonidine and oral acetazolamide to reduce intra-ocular pressure (IOP) variations after intravitreal bevacizumab injection (IVBV). Methods: 47 patients scheduled for IVBV (1.5 mg / 0.06 ml) will be randomly assigned to a pre-treatment 1 hour before IVBV with either 250 mg oral acetazolamide (DIA, 9 eyes), anterior chamber paracentesis immediate after IVBV (PAR, 15 eyes), topic brimonidine tartarate 1 hour before IVBV (BRI, 14 eyes), or no pre-treatment IBVB (CTR, 9 eyes). IOP will be measured 90 minutes before injection (baseline), just before injection, and at 3, 10, 20 and 30 minutes after the procedure.
Interventions
Sponsors
University of Sao Paulo
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* macular edema
Exclusion criteria
* pulmonary chronic problems * chronic renal failure * intraocular inflammation * drug or alcohol addiction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intra-ocular pressure variation after intra-vitreous injection of bevacizumab | — |
Countries
Brazil
Outcome results
None listed